IL315898A - Anxiety treatment - Google Patents
Anxiety treatmentInfo
- Publication number
- IL315898A IL315898A IL315898A IL31589824A IL315898A IL 315898 A IL315898 A IL 315898A IL 315898 A IL315898 A IL 315898A IL 31589824 A IL31589824 A IL 31589824A IL 315898 A IL315898 A IL 315898A
- Authority
- IL
- Israel
- Prior art keywords
- anxiety
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000083 | 2022-03-27 | ||
| EP22000086 | 2022-03-27 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| PCT/EP2023/057857 WO2023186816A1 (en) | 2022-03-27 | 2023-03-27 | Treatment of anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315898A true IL315898A (en) | 2024-11-01 |
Family
ID=86007166
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315898A IL315898A (en) | 2022-03-27 | 2023-03-27 | Anxiety treatment |
| IL315902A IL315902A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation |
| IL315897A IL315897A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315891A IL315891A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of bipolar disorder |
| IL315896A IL315896A (en) | 2022-03-27 | 2023-03-27 | Cognitive function therapy |
| IL315899A IL315899A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315902A IL315902A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation |
| IL315897A IL315897A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315891A IL315891A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of bipolar disorder |
| IL315896A IL315896A (en) | 2022-03-27 | 2023-03-27 | Cognitive function therapy |
| IL315899A IL315899A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US20250205199A1 (enExample) |
| EP (7) | EP4499076A1 (enExample) |
| JP (6) | JP2025511081A (enExample) |
| KR (6) | KR20250005181A (enExample) |
| CN (2) | CN119053327A (enExample) |
| AU (6) | AU2023246545A1 (enExample) |
| CA (6) | CA3255505A1 (enExample) |
| IL (6) | IL315898A (enExample) |
| WO (9) | WO2023186797A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| WO2022153266A1 (en) | 2021-01-15 | 2022-07-21 | Beckley Psytech Limited | Ergoline analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US20040234699A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| ATE489981T1 (de) | 2006-08-01 | 2010-12-15 | Stobi Gmbh & Co Kg | Ventilballon für inhalatoren |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| AU2020225766B2 (en) * | 2019-02-22 | 2025-10-30 | GH Research Ireland Limited | Compositions comprising 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for use in treating mental disorders |
| EA202192318A1 (ru) | 2019-02-22 | 2021-12-21 | Гх Рисерч Айрленд Лимитед | 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии |
| JP2022529781A (ja) * | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| KR20230024378A (ko) * | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
-
2023
- 2023-03-27 CA CA3255505A patent/CA3255505A1/en active Pending
- 2023-03-27 JP JP2024557755A patent/JP2025511081A/ja active Pending
- 2023-03-27 US US18/850,370 patent/US20250205199A1/en active Pending
- 2023-03-27 JP JP2024557191A patent/JP2025510912A/ja active Pending
- 2023-03-27 KR KR1020247035758A patent/KR20250005181A/ko active Pending
- 2023-03-27 CA CA3255348A patent/CA3255348A1/en active Pending
- 2023-03-27 IL IL315898A patent/IL315898A/en unknown
- 2023-03-27 EP EP23717036.0A patent/EP4499076A1/en not_active Withdrawn
- 2023-03-27 CN CN202380031464.6A patent/CN119053327A/zh active Pending
- 2023-03-27 CN CN202380030914.XA patent/CN119095595A/zh active Pending
- 2023-03-27 CA CA3255340A patent/CA3255340A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057827 patent/WO2023186797A1/en not_active Ceased
- 2023-03-27 EP EP23717043.6A patent/EP4499083A1/en active Pending
- 2023-03-27 EP EP23717042.8A patent/EP4499082A1/en active Pending
- 2023-03-27 US US18/850,362 patent/US20250241892A1/en active Pending
- 2023-03-27 IL IL315902A patent/IL315902A/en unknown
- 2023-03-27 EP EP23717412.3A patent/EP4499088A1/en active Pending
- 2023-03-27 CA CA3255343A patent/CA3255343A1/en active Pending
- 2023-03-27 US US18/850,383 patent/US20250205256A1/en not_active Abandoned
- 2023-03-27 WO PCT/EP2023/057842 patent/WO2023186806A1/en not_active Ceased
- 2023-03-27 US US18/851,346 patent/US20250241895A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057883 patent/WO2023186835A1/en not_active Ceased
- 2023-03-27 EP EP23717033.7A patent/EP4499073A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057876 patent/WO2023186829A1/en not_active Ceased
- 2023-03-27 AU AU2023246545A patent/AU2023246545A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057857 patent/WO2023186816A1/en not_active Ceased
- 2023-03-27 EP EP23717031.1A patent/EP4499226A1/en active Pending
- 2023-03-27 AU AU2023246543A patent/AU2023246543A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057867 patent/WO2023186820A1/en not_active Ceased
- 2023-03-27 AU AU2023246774A patent/AU2023246774A1/en active Pending
- 2023-03-27 AU AU2023242291A patent/AU2023242291A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057877 patent/WO2023186830A1/en not_active Ceased
- 2023-03-27 CA CA3255629A patent/CA3255629A1/en active Pending
- 2023-03-27 IL IL315897A patent/IL315897A/en unknown
- 2023-03-27 IL IL315891A patent/IL315891A/en unknown
- 2023-03-27 IL IL315896A patent/IL315896A/en unknown
- 2023-03-27 JP JP2024557759A patent/JP2025510369A/ja active Pending
- 2023-03-27 KR KR1020247035746A patent/KR20250005179A/ko active Pending
- 2023-03-27 AU AU2023246679A patent/AU2023246679A1/en active Pending
- 2023-03-27 EP EP23717035.2A patent/EP4499075A1/en active Pending
- 2023-03-27 US US18/851,343 patent/US20250213532A1/en active Pending
- 2023-03-27 JP JP2024557205A patent/JP2025510916A/ja active Pending
- 2023-03-27 KR KR1020247035718A patent/KR20250005176A/ko active Pending
- 2023-03-27 JP JP2024557758A patent/JP2025510368A/ja active Pending
- 2023-03-27 CA CA3255648A patent/CA3255648A1/en active Pending
- 2023-03-27 KR KR1020247035653A patent/KR20250005170A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057870 patent/WO2023186823A1/en not_active Ceased
- 2023-03-27 US US18/850,348 patent/US20250241891A1/en active Pending
- 2023-03-27 IL IL315899A patent/IL315899A/en unknown
- 2023-03-27 US US18/850,376 patent/US20250241893A1/en active Pending
- 2023-03-27 KR KR1020247035762A patent/KR20250005183A/ko active Pending
- 2023-03-27 AU AU2023244452A patent/AU2023244452A1/en active Pending
- 2023-03-27 JP JP2024557204A patent/JP2025512831A/ja active Pending
- 2023-03-27 WO PCT/EP2023/057873 patent/WO2023186826A1/en not_active Ceased
- 2023-03-27 KR KR1020247035659A patent/KR20240167879A/ko active Pending
- 2023-09-27 US US18/373,906 patent/US20240108602A1/en active Pending
- 2023-09-27 US US18/373,903 patent/US20240108601A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315896A (en) | Cognitive function therapy | |
| IL315503A (en) | Treatment methods | |
| IL320711A (en) | Treatment methods | |
| GB202201824D0 (en) | Methods of treatment | |
| GB202001353D0 (en) | Treatment of skin conditions | |
| GB202201819D0 (en) | Methods of treatment | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202313514D0 (en) | Treatment of inflammatory diseases | |
| GB202205715D0 (en) | Treatment of neutrophilic dermatoses | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202307686D0 (en) | Treatment of conditions | |
| IL325944A (en) | Treatment methods | |
| GB202101251D0 (en) | Treatment of conditions | |
| GB202118006D0 (en) | Methods of treatment | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202118007D0 (en) | Methods of treatment | |
| GB202108245D0 (en) | Methods of treatment | |
| GB202108242D0 (en) | Methods of treatment | |
| GB202202876D0 (en) | Method of treatment | |
| GB202102950D0 (en) | Method of treatment | |
| GB202110146D0 (en) | Treatment of respiratory conditions | |
| GB202311827D0 (en) | Treatment of neuroblastoma | |
| GB202018243D0 (en) | Method of treatment | |
| GB202005874D0 (en) | Methods of treatment |